A Novel Function for BRCA1 E3 Ligase Activity in Regulating PARP Inhibitor Sensitivity in HGSOC

Project summary

This project aims to understand why some ovarian cancers stop responding to a type of treatment called PARP inhibitors. We are studying how certain proteins, which normally help fix damaged DNA, might instead make cancer harder to treat when not properly controlled. By finding out how these proteins behave in cancer cells, we hope to discover new ways to predict which patients will benefit from treatment and develop better strategies to keep the treatment working longer. Our goal is to improve outcomes for people with ovarian cancer by personalizing and strengthening their therapy.

This grant was made possible in part by a generous donation from The Berger Family in memory of Sharon Berger.